# Open-Label Treatment Extension of Protocol MNTX 301

> **NCT01367600** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Terminal Illness

## Interventions

- **DRUG:** SC Methylnaltrexone (MNTX)

## Key facts

- **NCT ID:** NCT01367600
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01367600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01367600, "Open-Label Treatment Extension of Protocol MNTX 301". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01367600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*